FDA inspection
POINT Biopharma USA Inc: FDA inspection ending Jun 7, 2024
FDA inspection 1240823 · Voluntary Action Indicated (VAI) · Indianapolis, IN
Key facts
| Inspection ID | 1240823 |
|---|---|
| Firm | POINT Biopharma USA Inc |
| FEI number | 3017226344 |
| Address | 4850 W 78th St |
| City | Indianapolis |
| State | IN |
| ZIP | 46268-2385 |
| Fiscal year | 2024 |
| Inspection end date | Jun 7, 2024 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data